RITUXAN and AVASTIN do not infringe Sanofi’s CMV enhancer patents 25 Mar 2012Scott Beeser The Court of Appeals for the Federal Circuit recently upheld a summary judgement decision that neither rituximab nor trastuzumab infringes two Sanofi... Read More